Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

Article Abstract:

A randomized, noninferiority trails is conducted to examine whether efficiency can be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin on patients infected with hepatitis C virus (HCV) genotype 2 or 3. The results have shown an overall lower sustained virologic response rate than treatment with the standard 24-week regimen.

HEALTH SERVICES, All Other Miscellaneous Ambulatory Health Care Services, Disease Testing Programs, Health aspects, Drugs, Drug evaluation, Hepatitis C virus, Drug overview, Peginterferon alfa-2a

---

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C

Article Abstract:

Combination therapy with interferon alpha-2b and ribavirin may be more effective in patients with hepatitis C than interferon alpha-2b alone. Researchers randomly assigned 912 patients with chronic hepatitis C to either one of these treatments. The two drugs together were more effective than interferon alpha-2b alone, especially when taken for 48 weeks. Liver biopsies showed that patients taking both drugs had improved liver function. However, they were more likely to stop the treatment than those taking interferon alpha-2b alone.

Evaluation, Hepatitis C, Interferon alpha, Ribavirin

---

Similar abstracts:

• Abstracts: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. Telbivudine versus lamivudine in patients with chronic hepatitis B

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.